April 2019
Volume 5, Issue 5
This issue features a look at the pitfalls of presenting and interpreting clinical trial data, the latest advances in transplant presented at the 2019 TCT Meetings, and more.
Table of Contents
April 2019 Issue
Perish to Publish: Repeated Episodes of Peer Rejection During the Publication Process
In adults – sensitive adults, in particular – who consider themselves academics, repeated episodes of peer rejection can have serious emotional repercussions. We (David...
The Color of Blood and “Exohematology”
Spilled blood’s brilliant red color has a rich symbolic history. The crimson color chemistry of porphyrin-bound iron ions led our ancestors to equate red...
April 2019 Issue
Remembering Francesco Lo Coco, NYU Langone Health to Establish Center for Blood Cancers, and...
Remembering Francesco Lo Coco (1955 – 2019)
Francesco Lo Coco, MD, a renowned leukemia researcher and pioneer of targeted therapy, passed away on March 3,...
ASH Expands Global Initiative, Awards Research Award to Minority Scholar
ASH Expands Global Initiative With Research Award for Hematologists Outside North America
The American Society of Hematology (ASH) Global Research Award was established in 2018...
April 2019 Issue
Test Post App
Numbers don’t lie – except when people cause them to.
With an abundance of scientific research being presented and published, many health-care practitioners rely on...
Pulling Back the Curtain: Lukas Wartman, MD
In this edition, Lukas Wartman, MD, discusses his decision to go into medicine and his life as a doctor and a patient. Hear more from...
Reader Beware: Interpreting Clinical Trial Data
Numbers don’t lie – except when people cause them to.
With an abundance of scientific research being presented and published, many health-care practitioners rely on...
April 2019 Issue
Reader Responses: Management of a patient with long-term B12 deficiency
Here’s how readers responded to a You Make the Call question about 42-year-old female patient who has had very low B12 levels for at...
Management of a patient with long-term B12 deficiency
This month, Marilyn Telen, MD, discusses management of a patient with long-term B12 deficiency.
And don't forget to check out next month's clinical dilemma - send...
April 2019 Issue
Aggressive Imatinib Dose Escalation Shows No Improvement Over Standard Escalation in CML
For patients with newly diagnosed chronic myeloid leukemia (CML), aggressive dose escalation of imatinib failed to improve response and survival rates compared with a...
Can a Virtual Benign Hematology Consult Improve Access to and Quality of Care?
A multidisciplinary team of researchers developed a virtual benign hematology consultative service that can potentially reduce the time it takes a specialist to examine...
JULIET Analysis Finds Durable Responses With Tisagenlecleucel in DLBCL
Half of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) responded to tisagenlecleucel, and approximately two-thirds of responders are expected to remain...
Carfilzomib Versus Bortezomib: Comparing Proteasome Inhibitors in Newly Diagnosed Myeloma
Carfilzomib plus melphalan and prednisone (KMP) failed to improve survival outcomes for patients with newly diagnosed multiple myeloma (MM) compared with bortezomib plus melphalan...
Ibrutinib and Obinutuzumab Combo Granted Approval for CLL/SLL
The U.S. Food and Drug Administration (FDA) approved the combination of ibrutinib and obinutuzumab for the treatment of patients with treatment-naïve chronic lymphocytic leukemia/small...
FDA Approves Caplacizumab-yhdp for Acquired TTP
Caplacizumab-yhdp, a bivalent anti–von Willebrand factor nanobody, was approved for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with...
Liquid Biopsy Test Cleared for Use in CML
The U.S. Food and Drug Administration approved the QXDx AutoDG ddPCR System, a liquid biopsy test designed to precisely and reproducibly monitor molecular response...
New Treatment Approved for Hemophilia A
The U.S. Food and Drug Administration approved turoctocog alfa pegol, an extended half-life factor VIII (FVIII) molecule formerly known as N8-GP, for the treatment...
FDA Warns Consumers About “Young Blood” Plasma Infusions
Responding to the rising popularity of “anti-aging” plasma infusions from young adults, the U.S. Food and Drug Administration (FDA) has warned consumers that the...
Prognostic Impact of TP53 Mutations Varies in Patients With Complex Karyotype MDS
In an analysis of mutation data from patients with complex karyotype myelodysplastic syndromes (CK-MDS), the presence of TP53 mutations conferred a poor prognosis, but...
April 2019 Issue
A Safer Conditioning Regimen for Patients With Bone Marrow Failure and Short Telomeres?
A study of patients with bone marrow failure (BMF) and short telomeres found that a conditioning regimen that eliminates radiation and DNA-alkylating agents led...
Alemtuzumab Plus Myeloablative Conditioning Reduces Post-Transplant GVHD Risk
For younger patients with sickle cell disease (SCD) who are eligible for a hematopoietic cell transplantation (HCT), adding alemtuzumab lowered the risk of graft-versus-host...
